Syros Pharmaceuticals, Inc. announced on October 24, 2019, Alice Tsang Shaw, M.D., Ph.D. notified Board of Directors of her resignation from the Board effective immediately. Dr. Shaw’s resignation was made at the request of the Board in connection with a change in Dr. Shaw’s employment, to avoid the potential for a conflict between her role as a member of the Board and her anticipated responsibilities as the head of translational clinical oncology for the Novartis Institutes for Biomedical Research.